MAUDE Adverse Event Report: ABBOTT IRELAND DIAGNOSTICS DIVISION LONGFORD ARCHITECT ESTRADIOL

Model Number	7K72-25
Medical Device Problem Code	Incorrect, Inadequate or Imprecise Result or Readings (1535)
Health Effect - Clinical Code	No Known Impact Or Consequence To Patient (2692)
Type of Reportable Event	Malfunction
Additional Manufacturer Narrative
Age at time of event : (b)(6).Is for patient a.The age of patient b was not provided.All available patient information was included.No additional patient information was provided.Name and address; address 1: (b)(6).An in-house investigation confirmed that the drug mifepristone causes interference/cross-reactivity with the architect estradiol assay leading to falsely elevated estradiol results.A product correction letter was issued on 05feb2019 to all architect estradiol and alinity i estradiol customers who received one of the impacted lots.The product correction letter informs the customer that patients undergoing mifepristone therapy should not be tested with the architect estradiol or the alinity i estradiol assays for up to two weeks post their last dose.It also instructs the customer to review the letter with their medical director.The architect and alinity estradiol package inserts will be updated to include new information regarding interference/cross-reactivity between the architect and alinity estradiol assays and the drug mifepristone.
Event or Problem Description
The customer observed falsely elevated architect estradiol results for two patients.The following data was provided: patient a: (b)(6) female patient with ectopic pregnancy, (b)(6) 2020 initial result = 234 pg/ml, tested again after mifepristone treatment was >1000 pg/ml, repeat >1000 pg/ml, repeat at another hospital was 200 pg/ml.Patient b: pregnant female, (b)(6) 2020 initial result = 89 pg/ml, tested again after mifepristone treatment was >1000 pg/ml, repeat at another hospital with roche = 46 (units of measure not provided).No impact to patient management was reported.

• Brand Name: ARCHITECT ESTRADIOL
• Common Device Name: ESTRADIOL
• Manufacturer (Section D): ABBOTT IRELAND DIAGNOSTICS DIVISION LONGFORD; lisnamuck; co. longford; longford NA ; EI NA
• MDR Report Key: 10414318
• Report Number: 3005094123-2020-00176
• Device Sequence Number: 3539264
• Product Code: CHP
• UDI-Device Identifier: 00380740014711
• UDI-Public: 00380740014711
• Combination Product (Y/N): N
• Initial Reporter Country: CH
• PMA/510(K) Number: EXEMPT
• Number of Events Summarized: 1
• Summary Report (Y/N): N
• Reporter Type: Manufacturer
• Report Source: foreign,health professional
• Initial Reporter Occupation: Other Health Care Professional
• Remedial Action: Notification
• Type of Report: Initial
• Report Date (Section B): 08/17/2020

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Is this an Adverse Event Report?: No
• Is this a Product Problem Report?: Yes
• Operator of Device: Health Professional
• Device Expiration Date: 10/18/2020
• Device Model Number: 7K72-25
• Device Catalogue Number: 07K72-25
• Device Lot Number: 12208UI00
• Was Device Available for Evaluation?: No
• Type of Report(Section G): Thirty-Day
• Initial Date Received by Manufacturer: 08/12/2020
• Initial Report FDA Received Date: 08/17/2020
• Is This a Single-Use Device that was Reprocessed and Reused on a Patient? (Y/N): No
• If action reported to FDA under 21 USC 360i(g), list FDA-assigned Recall Number or include a statement: 3005094123-02/8/19-001-C
• Patient Sequence Number: 1
• Patient Age: 29 YR